最新！强生拟分拆骨科业务，又一百亿美元分拆案

Core Viewpoint - Johnson & Johnson plans to spin off its orthopedic business into an independent company named "DePuy Synthes" while raising its 2025 revenue forecast, exceeding Wall Street expectations [1][3]. Financial Performance - Johnson & Johnson expects 2025 product revenue to reach between $93.5 billion and $93.9 billion, an increase of approximately $300 million from previous estimates and higher than analysts' expectations of $93.4 billion [3]. - The company reported global sales of $24 billion for Q3 2025, a year-over-year increase of 6.8%, slightly above Wall Street's expectation of $23.75 billion [7]. - The innovative pharmaceuticals segment generated $15.563 billion in Q3 2025, accounting for 64.8% of total sales, with a year-over-year growth of 6.8% [7][8]. Business Strategy - The orthopedic business, which generated approximately $9.2 billion in revenue last year, accounted for about 10% of Johnson & Johnson's total revenue [5]. - The company initiated a two-year restructuring plan for its orthopedic business in 2023, focusing on exiting certain markets and discontinuing non-core products, laying the groundwork for the spin-off [5]. - Post-spin-off, DePuy Synthes is expected to become the largest global company focused on orthopedics, holding a leading market position in key product categories [5][7]. Leadership Changes - Namal Nawana has been appointed as the global president of DePuy Synthes, returning to the company after a career that includes significant roles at Johnson & Johnson and other firms [5][7]. Market Focus - Johnson & Johnson aims to concentrate on high-growth, high-margin areas such as oncology, immunology, neuroscience, surgical care, vision care, and cardiovascular sectors following the spin-off [5][7].